Treatment of inflammatory bowel disease:A review of medical therapy

查看全文 作　　者：Patricia L [1]Kozuch;Stephen B [2]Hanauer

机构地区：[1]Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States;[2]University of Chicago Hospitals, Department of Medicine, Section of Gastroenterology and Nutrition, Chicago, IL 60637, United States

出　　处：《World Journal of Gastroenterology》索引2008年第14卷第3期,共24页

摘　　要：Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract. While a cure remains elusive, both can be treated with medications that induce and maintain remission. With the recent advent of therapies that inhibit tumor necrosis factor (TNF) alpha the overlap in medical therapies for UC and CD has become greater. Although 5-ASA agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal. Antibiotics may have a limited role in the treatment of colonic CD. Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non- systemic steroids such as oral and rectal budesonide for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease. 6-mercaptopurine (6-MP) and its prodrug azathioprine are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while methotrexate may be used in both induction and maintenance of CD. Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC. 关键词：炎性肠病克罗恩氏病溃疡性结肠炎药物治疗

相关文献

参考文献（282）
引证文献（21）
耦合文献（9）

参考文献(282)

引证文献(21)

耦合文献(9)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Treatment of inflammatory bowel disease:A review of medical therapy

参考文献(282)

引证文献(21)

耦合文献(9)

用户提示